EyePoint Pharmaceuticals Inc (STU:PV3B)
€ 7.012 0.01 (0.14%) Market Cap: 382.82 Mil Enterprise Value: 152.78 Mil PE Ratio: 0 PB Ratio: 1.83 GF Score: 59/100

EyePoint Pharmaceuticals Inc to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD Transcript

Dec 04, 2020 / 05:00PM GMT
Release Date Price: €4.03 (-4.55%)
Operator

Good morning, and welcome to the EyePoint Pharmaceuticals' Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD. (Operator Instructions) Please note, this event is being recorded.

I would now like to turn the conference over to Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals. Please go ahead.

Nancy S. Lurker
EyePoint Pharmaceuticals, Inc. - President, CEO & Director

Thank you very much, and welcome, everyone. Thank you for joining us today to this important webcast. I think you'll find it very insightful and informative about a very serious eye disease, wet age-related macular degeneration and the treatments that are available and in the pipeline.

Next slide. We are a publicly traded company, and so we will be making forward-looking statements. I urge you to go to our website, where you can review all of our SEC statements.

Next slide. Thank you. Joining us today is a group of very prestigious retinal surgeons. I'm very pleased to welcome them: Dr. Bob Avery; Dr. Elias

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot